通过调节铁亡,SRS 16-86促进了糖尿病病的恢复
Yingchun Qiao1, Chao Sun2, Shunli Kan3
1NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Department of Clinical Laboratory, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
Experimental physiology
|May 30, 2024
概括
铁亡,一种新的细胞死亡,与糖尿病病 (DN) 有关. 在DN模型中,抑制剂SRS 16-86在改善功能和减少炎症方面表现有前途.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 糖尿病病 (DN) 是糖尿病 (DM) 的严重并发症.
- 细胞死亡途径,包括最近发现的铁亡,在DN病变发生过程中至关重要.
- 铁化在DN中的作用在很大程度上仍未被探索.
研究的目的:
- 调查铁死在DNA病理生理学中的作用.
- 为了评估ferroptosis抑制剂SRS 16-86在DN的老鼠模型中的治疗疗效.
主要方法:
- 已确立的糖尿病脏病 (DN) 在老鼠使用链毒素注射.
- 在DN脏中评估铁灭菌标志物 (铁,活性氧物种,脂质过氧化).
- 给药SRS 16-86并评估功能,组织学和炎症标志物.
主要成果:
- 在DN脏中检测到铁亡标记物.
- 在DN大鼠中,SRS 16-86治疗改善了功能和组织学.
- SRS 16-86上调的保护分子 (谷氨过氧化酶4,谷氨,系统x-) 和下调的脂质过氧化.
- SRS 16-86显著降低了炎症性细胞因子 (互白素1β,瘤缩因子α) 和细胞间粘附分子1.
结论:
- 铁亡与糖尿病病的病理机制密切相关.
- 铁灭抑制剂SRS 16-86显示出对DN的显著治疗潜力.
- SRS 16-86可能代表糖尿病病的新型治疗策略.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
397
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
554
相关概念视频
01:16Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
01:11Renal Failure: Dose Adjustments
84
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
84